T-cell depletion with anti-thymocyte globulin (ATG) favours superior overall survival and lowers rates of relapse and GVHD when compared to alemtuzumab in patients undergoing allogeneic haematopoietic stem cell transplantation for myelofibrosis: A retrospective single centre analysis